-J Montaner Researcher Activity Profile

Research Author Detailed Information 

J Montaner Publication Rate By Year

J Montaner has published 1 paper(s) in 2002, 1 paper(s) in 2004, 1 paper(s) in 2005, 1 paper(s) in 2006, 22 paper(s) in 2007, 10 paper(s) in 2008, for a total of 36 research publications in total.

J J Montaner Author Information

LAST NAME: montaner

FIRST NAME: J

INITIALS: j

AFFILIATION:

Papers

J Montaner's Publication Record

1. Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA. Year Published: 2007
Department of Pharmacology, University of Liverpool, Liverpool, UK. microhaart@aol.com
2. [Posterior spinal artery infarction and nonbacterial thrombotic endocarditis] Year Published: 2002
3. Prevalence and correlates of cervical cancer screening among injection drug users. Year Published: 2006
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
4. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Year Published: 2007
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, Canada. tkerr@cfenet.ubc.ca
5. Barriers and facilitators to methadone maintenance therapy use among illicit opiate injection drug users in Vancouver. Year Published: 2007
British Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada.
6. Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets. Year Published: 2007
Canadian HIV Trials Network, Pacific Region, St Paul's Hospital, and Healthy Heart Program, St Paul's Hospital, Vancouver, British Columbia, Canada. lena.normen@voh.ca
7. [Biological markers in spontaneous intracerebral hemorrhage] Year Published: 2007
8. Income generating activities of people who inject drugs. Year Published: 2007
British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia V6Z 1Y6, Canada.
9. [Private mutations in the myophosphorylase gene: the first case in a PATIENT of Latin American descent] Year Published: 2007
Universidad de Zaragoza, 50013 Zaragoza, Espana.
10. [The therapeutic potential of endothelial progenitor cells in ischaemic stroke.] Year Published: 2007
Hospital General Universitari Vall d'Hebron, Barcelona, Espana.
11. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Year Published: 2007
Stroke Unit, Department of Neurology, Universitat de Lleida, Hospital Universitari Arnau de Vilanova de Lleida, Avda Rovira Roure 80, Lleida 25198, Spain. 34271fpg@comb.es
12. Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets. Year Published: 2007
Canadian HIV Trials Network, Pacific Region, St Paul's Hospital, and Healthy Heart Program, St Paul's Hospital, Vancouver, British Columbia, Canada. lena.normen@voh.ca
13. Crystal methamphetamine use associated with non-fatal overdose among a cohort of injection drug users in Vancouver. Year Published: 2007
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC Canada, V6Z 146.
14. Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation. Year Published: 2007
15. Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA. Year Published: 2007
Department of Pharmacology, University of Liverpool, Liverpool, UK. microhaart@aol.com
16. Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator related hemorrhagic transformation. Year Published: 2007
17. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Year Published: 2007
Stroke Unit, Department of Neurology, Universitat de Lleida, Hospital Universitari Arnau de Vilanova de Lleida, Avda Rovira Roure 80, Lleida 25198, Spain. 34271fpg@comb.es
18. Leukaemia inhibitory factor is over-expressed by ischaemic brain tissue concomitant with reduced plasma expression following acute stroke. Year Published: 2008
The Department of Biology, Chemistry and Health Science, Manchester Metropolitan University, Manchester, UK. m.a.slevin@mmu.ac.uk
19. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Year Published: 2008
Neurovascular Research Laboratory, Neurovascular Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 31862jmv@comb.es
20. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. Year Published: 2007
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. milos.opravil@usz.ch
21. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. Year Published: 2008
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
22. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Year Published: 2005
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
23. Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation. Year Published: 2007
24. [The therapeutic potential of endothelial progenitor cells in ischaemic stroke] Year Published: 2007
25. Leukaemia inhibitory factor is over-expressed by ischaemic brain tissue concomitant with reduced plasma expression following acute stroke. Year Published: 2008
The Department of Biology, Chemistry and Health Science, Manchester Metropolitan University, Manchester, UK. m.a.slevin@mmu.ac.uk
26. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Year Published: 2008
Neurovascular Research Laboratory, Neurovascular Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 31862jmv@comb.es
27. Income generating activities of people who inject drugs. Year Published: 2007
British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia V6Z 1Y6, Canada.
28. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. Year Published: 2004
Department of Medicine, Division of Infectious Diseases, University of California, San Diego, AntiViral Research Center, CA 92103, USA. ftorriani@ucsd.edu
29. [Biological markers in spontaneous intracerebral hemorrhage] Year Published: 2007
Laboratorio de Investigación Neurovascular y Unidad de Ictus, Hospital Vall d'Hebron, Departamento de Medicina, Universidad Autónoma de Barcelona, Hospital de la Vall d'Hebron, Barcelona. 35070pdm@comb.es
30. [Private mutations in the myophosphorylase gene: the first case in a patient of Latin American descent] Year Published: 2007
Universidad de Zaragoza, 50013 Zaragoza, Espana.
31. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. Year Published: 2008
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. aanema@cfenet.ubc.ca
32. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. Year Published: 2007
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. milos.opravil@usz.ch
33. Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Year Published: 2008
British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, Canada. emills@cihhrs.org
34. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Year Published: 2008
35. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Year Published: 2008
36. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. Year Published: 2008
Biostatistic Unit, Hospital Clinic, Spain.